Caris Life Sciences, Inc. (CAI)
31.11
+0.40
(+1.30%)
USD |
NASDAQ |
Oct 20, 16:00
31.14
+0.03
(+0.10%)
Pre-Market: 08:00
Caris Life Sciences Research and Development Expense (TTM) : 117.14M for June 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 117.14M |
| March 31, 2026 | 109.83M |
| December 31, 2025 | 101.58M |
| September 30, 2025 | 96.85M |
| Date | Value |
|---|---|
| June 30, 2025 | 102.87M |
| March 31, 2025 | 102.61M |
| December 31, 2024 | 113.92M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| CareDx, Inc. | 79.87M |
| Natera, Inc. | 787.38M |
| Myriad Genetics, Inc. | 105.80M |
| BioRestorative Therapies, Inc. | 9.374M |
| Exagen, Inc. | 6.466M |